Castle Biosciences, Inc.
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Medical Monitoring
- Market Focus:
- Nationally (across the country)
About Us
Castle Biosciences is a leading diagnostic company focused on transforming disease management by keeping people first…
The patients who benefit from the information that our advanced diagnostic tests provide
The clinicians who use our tests to guide disease management decisions
Our talented and valued employees
Our investors
For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our tests provide.
Our innovative tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions provide personalized, clinically actionable information to clinicians and patients to guide treatment decisions and improve health outcomes.
Our Mission and Vision
Our Mission
Improving health through innovative tests that guide patient care
Our Vision
To transform disease management by keeping people first: patients, clinicians, employees, and investors
Our History
Castle Biosciences was founded by Derek Maetzold who believed that traditional methods to determine cancer patients’ prognosis could be improved by newly emerging techniques in molecular biology. We continue to focus on transforming disease management in areas of unmet clinical need through the development and marketing of innovative diagnostic and prognostic tests that guide patient care.